Earnings and revenue topped consensus calls but the shares whipsawed after investors decided they could’ve gotten more. 🚀 Nvidia Delivers Monster Quarter Nvidia NVDA posted another eye-watering earnings report Wednesday, with April-quarter revenue soaring 85% year over year to a record $81.6 billion. Analysts were looking for $78.9 billion. Nvidia casually cleared that bar like it was a garden hos...
Earnings and revenue topped consensus calls but the shares whipsawed after investors decided they could’ve gotten more. 🚀 Nvidia Delivers Monster Quarter Nvidia NVDA posted another eye-watering earnings report Wednesday, with April-quarter revenue soaring 85% year over year to a record $81.6 billion. Analysts were looking for $78.9 billion. Nvidia casually cleared that bar like it was a garden hose. NVDA Net income came in at a staggering $58.3 billion, more than triple last year’s level and roughly 36% above Wall Street expectations. At this point, Nvidia earnings reports are starting to look less like quarterly updates and more like cheat codes. Chief Executive Jensen Huang summed up the AI frenzy in a few words: “Demand has gone parabolic.” Translation: everybody wants chips, yesterday preferably, because the race to build AI agents is turning into a full-scale corporate arms race. 💾 Data Centers Print Money Nvidia’s growth engine remains its data-center business, where cloud giants and AI developers continue vacuuming up GPUs — graphics processing units, the specialized chips powering artificial intelligence training and inference workloads. Networking hardware sales tripled from a year ago to a record $14.8 billion, another sign that AI infrastructure spending is no longer just about chips. Companies are now building entire AI ecosystems, complete with servers, networking gear and enough electricity usage to light a small nation. The company also announced an $80 billion stock buyback and boosted its quarterly dividend from a symbolic one cent to 25 cents a share. That’s Wall Street’s version of bringing champagne bottles to the earnings call. 📉 So Why Did the Stock Fall?
Getty Images Tencent Music ( TME ) reported 1Q26 revenue and earnings that came largely in line with consensus. The quarter can be characterized by both puts and takes. We are positive on the regulatory approval of the Ximalaya acquisition, which clears the path for TME to become a meaningful player in the long-form audio market, an area that TME has historically lacked presence. We were also enco...
Getty Images Tencent Music ( TME ) reported 1Q26 revenue and earnings that came largely in line with consensus. The quarter can be characterized by both puts and takes. We are positive on the regulatory approval of the Ximalaya acquisition, which clears the path for TME to become a meaningful player in the long-form audio market, an area that TME has historically lacked presence. We were also encouraged to see IP and offline monetization continue to show resilience, which indicates that TME is moving away from a simple audio app to a comprehensive ecosystem offering performance-related businesses such as concerts and merchandise. Finally, advertising growth is driven by the diversification of ad formats and is proving more resilient amid a soft macro. On the other hand, signs of competition are not abating, with S&M spending coming in ahead of revenue growth, with management explicitly attributing this to intensifying competition and the need to mitigate the impact of user churn. This indicates that defending the current user base is becoming significantly more expensive. In addition, signs of involution (i.e., disorderly price competition from ByteDance) continue to be a challenge, and we wonder if TME can have the discipline to meet the conditional approval criteria of not entering an intense competition with ByteDance. Despite a competitive environment and user churn risk, we remain bullish on TME as we believe the narrative has shifted from user growth to ecosystem expansion in the wake of the Ximalaya acquisition. We believe that the acquisition of Ximalaya will be a game-changer for TME as it materially changes the business fundamentals from a pure audio app to an audio ecosystem. If investors believe the Ximalaya acquisition will successfully offset the user churn and that the audio ecosystem story will enhance stickiness and raise ARPU, then there is a reason to be bullish. Otherwise, the bullish thesis would be broken. A beat and lower quarter TME's Q1 was ...
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Interim financial results for the first quarter of 2026. Carsten Buhl, BioPorto’s Chief Executive Officer (CEO), comments “We have kicked off 2026 in line with our pla...
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, Denmark, May 21, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Interim financial results for the first quarter of 2026. Carsten Buhl, BioPorto’s Chief Executive Officer (CEO), comments “We have kicked off 2026 in line with our plan. We divested our antibody business and thereby further sharpened our focus on NGAL and strengthened our financial position. We have solid revenue growth driven by increasing adoption of our NGAL products, particularly in the U.S. Research Use Only (RUO) market. Further, we now have the KDIGO’s draft 2026 guideline, that reinforces the global shift toward earlier identification and intervention related to acute kidney injury. And we have submitted our Food and Drug Administration (FDA) pre-submission package, marking an important step toward a future U.S. 510(k) clearance for the adult urine NGAL. All in all, a good quarter, and we remain on track with our Forward Strategy.” (DKK million) Q1 2026 Q1 2025 Change (Pct) Full Year Guidance Total Revenue 9.4 7.7 23% 38-48 Total NGAL Revenue 6.0 4.5 33% 33-42 Adj. EBITDA loss 17.9 28.1 -36% 58-68 Financial highlights For Q1 2026, total NGAL revenue increased to DKK 6.0 million, which is an 33% increase compared to Q1 in 2025 (48% at constant exchange rate (CER)). The growth was driven by an increase in US NGAL Research Use Only (RUO) sales. For Q1 2026, revenue amounted to DKK 9.4 million (DKK 7.7 million for the same period in 2025). Revenue increased by 23% (32% at CER) in Q1 2026 compared to Q1 in 2025, and is mainly driven by US NGAL RUO and NGAL distributors revenue. Adjusted EBITDA loss in Q1 2026 amounted to DKK 17.9 million, which is a decrease of 36% compared to adj. EBITDA loss in Q1 2025 of DKK 28.1 million, and in line with expectations. As of March 31, 2026, the Company’s cash position was DKK 39.6 million compared ...
21. maj 2026 Meddelelse nr. 11 BioPorto annoncerer det midlertidige resultat for første kvartal af 2026 København, Danmark, 21. maj 2026 (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH:BIOPOR) offentliggjorde i dag de foreløbige finansielle resultater for første kvartal af 2026. Carsten Buhl, BioPortos administrerende direktør (CEO), udtaler: "Vi har startet 2026 i...
21. maj 2026 Meddelelse nr. 11 BioPorto annoncerer det midlertidige resultat for første kvartal af 2026 København, Danmark, 21. maj 2026 (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller Selskabet) (CPH:BIOPOR) offentliggjorde i dag de foreløbige finansielle resultater for første kvartal af 2026. Carsten Buhl, BioPortos administrerende direktør (CEO), udtaler: "Vi har startet 2026 i tråd med vores plan. Vi frasolgte vores antistofforretning og skærpede dermed yderligere vores fokus på NGAL hvilket ligeledes styrkede vores finansielle position. Vi har solid omsætningsvækst drevet af øget adoption af vores NGAL-produkter, især på det amerikanske Research Use Only (RUO) marked. Derudover har vi nu udkastet til KDIGO's 2026-retningslinjer, som understreger det globale skift mod tidligere identifikation og intervention relateret til akut nyreskade. Vi har indsendt vores Food and Drug Administration (FDA) pre-submission pakke, hvilket markerer et vigtigt skridt mod en fremtidig amerikansk 510(k)-godkendelse for voksen urin NGAL. Alt i alt et godt kvartal, og vi forbliver på sporet med vores Forward strategi.” (DKK millioner) Q1 2026 Q1 2025 Forandring (PCT) 2026 Helårsforventninger Samlet omsætning 9.4 7.7 23% 38-48 Samlet NGAL-indtægter 6.0 4.5 33% 33-42 Justeret EBITDA-tab 17.9 28.1 -36% 58-68 Økonomiske højdepunkter I første kvartal 2026 vækstede den samlede NGAL-omsætning til 6,0 millioner DKK, hvilket er en stigning på 33 % sammenlignet med første kvartal i 2025 (48 % ved konstant valutakurs (CER)). Væksten blev drevet af en stigning i salget af US NGAL Research Use Only (RUO). I første kvartal 2026 udgjorde omsætningen 9,4 millioner DKK (7,7 millioner DKK for samme periode i 2025). Omsætningen steg med 23 % (32 % ved CER) i første kvartal 2026 sammenlignet med første kvartal i 2025, og drives hovedsageligt af US NGAL RUO og NGAL-distributørers indtægter. Det justerede EBITDA-tab i første kvartal 2026 udgjorde 17,9 millioner DKK, hvilket er et fald på ...
Officers who defended Capitol from rioters sue to block payouts from fund toggle caption John Minchillo/AP WASHINGTON — Two police officers who helped defend the U.S. Capitol from an attack by a mob of President Donald Trump's supporters sued on Wednesday to block anyone — including Jan. 6, 2021, rioters — from receiving payouts from a new $1.776 billion settlement fund for people who claim to be ...
Officers who defended Capitol from rioters sue to block payouts from fund toggle caption John Minchillo/AP WASHINGTON — Two police officers who helped defend the U.S. Capitol from an attack by a mob of President Donald Trump's supporters sued on Wednesday to block anyone — including Jan. 6, 2021, rioters — from receiving payouts from a new $1.776 billion settlement fund for people who claim to be victims of politically motivated prosecutions. The officers' attorneys filed the federal lawsuit a day after acting Attorney General Todd Blanche defended the fund's creation during a congressional hearing. Blanche, a personal attorney for Trump before joining the Justice Department, wouldn't rule out the possibility that rioters who assaulted police on Jan. 6 would be eligible for fund payouts. The lawsuit claims the government's "Anti-Weaponization Fund" is an illegal slush fund that Trump will use to "finance the insurrectionists and paramilitary groups that commit violence in his name." It describes the fund's creation as "the most brazen act of presidential corruption this century" and calls for dissolving it. Sponsor Message "No statute authorizes its creation, the settlement on which it is premised is a corrupt sham, and its design violates the Constitution and federal law," the suit says. The fund stems from a settlement of Trump's $10 billion lawsuit against the IRS over the leak of his tax returns. It's designed to compensate those who believe they were mistreated by prior administrations' Justice Department. Decisions on payouts will be made by a five-member commission appointed by the attorney general. More than 100 police officers were injured during the Capitol riot. Nearly 1,600 people were charged with Jan. 6-related crimes, but Trump used his pardon powers to erase all of those cases in a sweeping act of clemency last year. The plaintiffs suing Trump over the fund are Metropolitan Police Department officer Daniel Hodges and former U.S. Capitol Police office...
Editor's note: Seeking Alpha is proud to welcome Logan Richards as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Carmen Ruiz alonso/iStock via Getty Images Executive Summary Unicycive Therapeutics ( UNCY ) is a ...
Editor's note: Seeking Alpha is proud to welcome Logan Richards as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Carmen Ruiz alonso/iStock via Getty Images Executive Summary Unicycive Therapeutics ( UNCY ) is a small biotech company specializing in treatments for chronic kidney disease and hyperphosphatemia. At the time of writing, the company is trading at roughly $8/share, with a market cap of around $210 million and a float of nearly 26 million shares. The company has $55 million cash in hand, which should allow them to comfortably operate into 2027, according to a press release posted March 30, 2026. This means 1) the cash floor for this company is around $2 a share and 2) the market has pegged the value of their entire pipeline at about $6 a share, or $156 million total. To keep things simple, I decided to focus on their lead asset, oxylanthanum carbonate (OLC). For this analysis, I wanted to determine if UNCY is intrinsically undervalued based on just this one drug. I'm putting a pin on everything else because OLC also has an upcoming catalyst I'm highly interested in watching. The Pill Burden Problem In my opinion, Unicycive's most compelling asset is a rare-earth mineral drug, oxylanthanum carbonate. OLC is being developed as a next-generation phosphate binder that utilizes UNCY's nanoparticle technology to increase the phosphate-binding potential of the drug. Critically, OLC has a PDUFA target action date of June 29, 2026, which is when the FDA expects to decide on whether the company can begin marketing the drug. For context, lanthanum carbonate has and currently still is used to treat high phosphate that results from kidney disease, with clinical data on the drug spanning years at this point. However, the pill burden patients must endure, many of whom are not compliant ...